癌症恶病质市场预计在预测期内（2025-2034年）将以8.9%的年复合增长率呈现令人印象深刻的增长轨迹 DelveInsight-动脉网

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034)

CISION 等信源发布 2025-07-10 05:31



可切换为仅中文







The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1), and TCMCB07, among others. Additionally, the rising prevalence of cancer cachexia, driven by factors such as an aging population, improved cancer survival rates that allow more patients to develop cachexia, increasing incidence of high-risk tumor types (e.g., lung and pancreatic cancers), and enhanced diagnostic awareness, continues to challenge clinical management..

预计癌症恶病质市场将在7MM地区扩张，这得益于创新疗法的推出，如ponsegromab（PF-06946860）、S-吲哚洛尔苯甲酸酯（ACM-001.1）和TCMCB07等。此外，癌症恶病质患病率的上升受多种因素驱动，例如人口老龄化、癌症生存率提高使得更多患者发展为恶病质、高风险肿瘤类型（如肺癌和胰腺癌）发病率增加以及诊断意识的提高，这些持续对临床管理构成挑战。

LAS VEGAS

拉斯维加斯

，

July 9, 2025

2025年7月9日

/PRNewswire/ -- DelveInsight's

/PRNewswire/ -- DelveInsight的

Cancer Cachexia Market Insights

癌症恶病质市场洞察

report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [

报告包括对当前治疗实践、癌症恶病质新兴药物、各疗法的市场份额以及2020年至2034年当前和预测的市场规模的全面理解，分为7个主要市场。

the United States

美国

, the EU4 (

，欧盟4（

Germany

德国

，

France

法国

，

Italy

意大利

, and

，以及

Spain

西班牙

) and the

) 和

United Kingdom

英国

, and Japan].

，以及日本]。

Key Takeaways from the Cancer Cachexia Market Report

癌症恶病质市场报告的关键要点

According to DelveInsight's analysis, the market size for cancer cachexia was found to be

根据DelveInsight的分析，癌症恶病质的市场容量被发现是

USD 475 million

4.75亿美元

in the 7MM in 2024.

在2024年的7MM中。

The United States

美国

accounted for the highest market size of cancer cachexia, approximately

占据了癌症恶病质最大的市场规模，约为

58%

of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (

2024年在7MM的总市场规模中，与其它主要市场（即欧盟四国）相比，

Germany

德国

，

France

法国

，

Italy

意大利

, and

，以及

Spain

西班牙

), the

），这个

United Kingdom

英国

, and

，以及

Japan

日本

。

The current standard of care for cancer cachexia, which includes

当前癌症恶病质的护理标准包括

progestins, corticosteroids, and Tumor Necrosis Factor (TNF) inhibitors

孕激素、皮质类固醇和肿瘤坏死因子（TNF）抑制剂

, among others, provides modest clinical benefit and, as per DelveInsight estimates, generated approximately

，以及其他方面，提供了适度的临床益处，并且根据DelveInsight的估计，产生了大约

USD 470 million

4.7亿美元

in 2024, highlighting a substantial unmet need in this space.

2024年，突显了这一领域存在大量未满足的需求。

According to DelveInsight's estimates, the total diagnosed prevalent cases of cancer cachexia in the 7MM were around

根据DelveInsight的估计，7MM中癌症恶病质的总确诊患病病例数约为

1.4 million

140万

in 2024, which are expected to rise by 2034.

在2024年，这一数字预计到2034年还会上升。

Leading companies such as

领先企业如

Pfizer

辉瑞

，

Actimed Therapeutics

阿克蒂米德治疗公司

，

Endevica Bio

恩德维卡生物

，

AVEO Oncology

AVEO肿瘤学

(

an LG Chem company

LG化学公司

), and others are actively advancing novel therapies for cancer cachexia, with several promising drugs expected to enter the market in the coming years.

），其他公司也在积极推进癌症恶病质的新疗法，预计未来几年将有几种有希望的药物进入市场。

The promising cancer cachexia therapies in the pipeline include

目前在研发中的有希望的癌症恶病质治疗方法包括

Ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1; MT-102), TCMCB07, Rilogrotug (AV-380),

波塞格罗单抗 (PF-06946860)，S-吲哚洛尔苯甲酸酯 (ACM-001.1; MT-102)，TCMCB07，利洛格罗图 (AV-380)，

and others.

和其他人。

Estimates suggest that

估计表明

ponsegromab (PF-06946860)

蓬塞格罗马布（PF-06946860）

is expected to generate approximately

预计将会产生大约

USD 425 million

4.25亿美元

in the 7MM by 2034.

到 2034 年在 7MM 中。

Discover which therapies are expected to grab the major cancer cachexia treatment market share @

了解哪些疗法有望占据主要的癌症恶病质治疗市场份额 @

Cancer Cachexia Market Report

癌症恶病质市场报告

Cancer Cachexia Overview

癌症恶病质概述

Cancer cachexia is a multifactorial wasting disorder commonly observed in advanced stages of cancer. It is characterized by a progressive depletion of skeletal muscle and fat, resulting in profound weakness. Unlike general malnutrition, cancer cachexia does not improve with nutritional support alone.

癌症恶病质是一种多因素导致的消耗性疾病，常见于癌症晚期阶段。其特征是骨骼肌和脂肪的逐渐消耗，导致严重的虚弱。与一般的营养不良不同，癌症恶病质仅靠营养支持无法改善。

The condition is largely driven by systemic inflammation, with cytokines, proteins released by both tumor and host cells, playing a central role. These inflammatory mediators disrupt normal metabolic processes, triggering appetite loss (anorexia), insulin resistance (reduced glucose utilization), and a metabolic shift favoring tissue breakdown (catabolism) over tissue synthesis.

该状况主要由系统性炎症驱动，细胞因子（由肿瘤和宿主细胞释放的蛋白质）在其中起到核心作用。这些炎症介质破坏正常的代谢过程，引发食欲减退（厌食）、胰岛素抵抗（葡萄糖利用减少）以及代谢转向，倾向于组织分解（分解代谢）而非组织合成。

This leads to a persistent energy deficit, especially in aggressive cancers such as pancreatic, lung, and head and neck cancers..

这会导致持续的能量不足，尤其是在胰腺癌、肺癌以及头颈癌等侵袭性癌症中。

Diagnosing cancer cachexia is challenging due to the absence of a single diagnostic marker, requiring a comprehensive evaluation. This includes nutritional assessment tools like the Patient-Generated Subjective Global Assessment (PG-SGA) or Mini Nutritional Assessment (MNA), body composition analysis through imaging methods like computed tomography (CT), the gold standard, or alternatives such as dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA), as well as muscle strength tests like handgrip dynamometry. .

由于缺乏单一的诊断标志物，诊断癌症恶病质具有挑战性，需要进行全面评估。这包括使用营养评估工具，如患者生成的主观全面评估（PG-SGA）或微型营养评估（MNA），通过成像方法进行身体成分分析，如计算机断层扫描（CT）这一金标准，或双能X射线吸收法（DXA）和生物电阻抗分析（BIA）等替代方法，以及通过握力计测试肌肉力量。

Laboratory indicators such as low serum albumin and elevated C-reactive protein (CRP) can aid diagnosis but lack specificity. Composite scoring systems like the modified Glasgow Prognostic Score (mGPS) and the Cancer Cachexia Score (CASCO) offer a more holistic approach by integrating clinical, metabolic, and functional parameters to stage the condition and predict clinical outcomes..

实验室指标如低血清白蛋白和C反应蛋白（CRP）升高可辅助诊断，但缺乏特异性。综合评分系统如改良格拉斯哥预后评分（mGPS）和癌症恶病质评分（CASCO）通过整合临床、代谢和功能参数提供了更全面的方法，用于分期病情并预测临床结果。

Cancer Cachexia Epidemiology Segmentation

癌症恶病质流行病学细分

The cancer cachexia epidemiology section provides insights into the historical and current cancer cachexia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

癌症恶病质流行病学部分提供了对历史和当前癌症恶病质患者群体的洞察，以及对七大主要市场（7MM）的预测趋势。它通过探讨众多研究和关键意见领袖的观点，帮助识别当前和预测患者趋势的原因。

The cancer cachexia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

癌症恶病质市场报告提供了2020-2034年研究期间的流行病学分析，涵盖七大主要市场（7MM），并细分为：

Total Diagnosed Prevalent Cases of Cancer Cachexia

癌症恶病质的总诊断患病数

Gender-specific Cases of Cancer Cachexia

性别特异性癌症恶病质病例

Tumor type-specific Cases of Cancer Cachexia

肿瘤类型特异性癌症恶病质病例

Age-specific Cases of Cancer Cachexia

癌症恶病质的年龄特异性病例

Cancer Cachexia Treatment Market

癌症恶病质治疗市场

Progestational agents like

孕激素类药物像

MEGACE (megestrol) and medroxyprogesterone

MEGACE（甲地孕酮）和甲羟孕酮

are known to stimulate appetite and promote weight gain in individuals suffering from anorexia and cachexia. A randomized, prospective clinical study comparing megestrol (800 mg/day) with dexamethasone (0.75 mg four times daily) found that both drugs had similar effects on enhancing appetite. However, megestrol was more frequently associated with thromboembolic complications, whereas dexamethasone was linked to side effects such as muscle weakness, Cushingoid appearance, and peptic ulcers..

已知能够刺激食欲，并促进患有厌食症和恶病质的个体体重增加。一项随机、前瞻性临床研究比较了甲地孕酮（每天800毫克）和地塞米松（每天四次，每次0.75毫克）的效果，发现这两种药物在增强食欲方面具有相似的作用。然而，甲地孕酮更容易引发血栓栓塞并发症，而地塞米松则与肌肉无力、库欣样外观和消化性溃疡等副作用相关。

Although

尽管

corticosteroids and progestational

皮质类固醇和孕激素

agents

代理

have shown effectiveness in treating cancer-related anorexia and cachexia, they generally do not produce significant long-term benefits for most patients. As a result, alternative interventions, including enteral and parenteral nutrition, have been widely explored. In

在治疗癌症相关的厌食症和恶病质方面显示出有效性，但通常对大多数患者而言，它们并不能带来显著的长期益处。因此，包括肠内和肠外营养在内的替代干预措施已被广泛探索。在

January 2021

2021年1月

，

Ono Pharmaceutical's ADLUMIZ (Anamorelin)

ONO制药的ADLUMIZ（Anamorelin）

was approved in

被批准于

Japan

日本

for the treatment of cancer cachexia in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

用于治疗非小细胞肺癌（NSCLC）和结直肠癌（CRC）患者的癌症恶病质。

Cytokine-targeted therapies have also been investigated. These therapies affect a range of tissues, including bone marrow, muscle, liver, fat, endothelial cells, and neurons, triggering complex biological responses that contribute to the muscle and weight loss seen in cachexia. Key cytokines implicated include tumor necrosis factor (TNF)-α, interleukins IL-1 and IL-6, and interferon-γ (IFN-γ).

细胞因子靶向疗法也已被研究。这些疗法影响多种组织，包括骨髓、肌肉、肝脏、脂肪、内皮细胞和神经元，触发复杂的生物反应，从而导致恶病质中出现的肌肉减少和体重下降。关键的细胞因子包括肿瘤坏死因子（TNF）-α、白细胞介素IL-1和IL-6，以及干扰素-γ（IFN-γ）。

These molecules share similar metabolic roles and often act in a coordinated or synergistic manner. Therefore, treatment strategies have focused on inhibiting either their production or their downstream effects..

这些分子具有相似的代谢作用，通常以协调或协同的方式发挥作用。因此，治疗策略集中在抑制它们的产生或下游效应上。

To know more about cancer cachexia treatment guidelines, visit @

要了解更多关于癌症恶病质治疗指南的信息，请访问 @

Cancer Cachexia Treatment Options

癌症恶病质治疗选项

Cancer Cachexia Pipeline Therapies and Key Companies

癌症恶病质管线疗法及关键公司

Ponsegromab (PF-06946860): Pfizer

Ponsegromab（PF-06946860）：辉瑞

S-pindolol benzoate (ACM-001.1; MT-102): Actimed Therapeutics

S-吲哚洛尔苯甲酸酯 (ACM-001.1; MT-102): Actimed Therapeutics

TCMCB07: Endevica Bio

TCMCB07：Endevica 生物

Rilogrotug (AV-380): AVEO Oncology (an LG Chem company)

里洛格罗图 (AV-380): AVEO肿瘤学公司（LG化学公司旗下）

Discover more about cancer cachexia drugs in development @

了解更多关于正在开发的癌症恶病质药物 @

Cancer Cachexia Clinical Trials

癌症恶病质临床试验

Cancer Cachexia Market Dynamics

癌症恶病质市场动态

The cancer cachexia market dynamics are expected to change in the coming years. Cancer cachexia affects a significant portion of

预计癌症恶病质市场动态将在未来几年发生变化。癌症恶病质影响了很大一部分患者。

late-stage cancer patients

晚期癌症患者

, creating a strong demand for effective therapies and presenting a valuable opportunity for companies to develop treatments, given the current

，由于目前对有效疗法的强烈需求，为公司开发治疗方案提供了宝贵的机会，鉴于当前的情况

lack of options and limited market competition

缺乏选择和有限的市场竞争

。

Furthermore, potential therapies are being investigated for the treatment of cancer cachexia, and it is safe to predict that the treatment space will significantly impact the cancer cachexia market during the forecast period. Moreover, the

此外，正在研究用于治疗癌症恶病质的潜在疗法，可以肯定地预测，在预测期内，治疗领域将对癌症恶病质市场产生重大影响。而且，

anticipated introduction of emerging therapies

预期的新兴疗法引入

with improved efficacy and a further

随着疗效的提高和进一步的

improvement in the diagnosis rate

诊断率的提高

are expected to drive the growth of the cancer cachexia market in the 7MM.

预计将在七大市场中推动癌症恶病质市场的增长。

However, several factors may impede the growth of the cancer cachexia market. Studies have shown that cancer patients with cachexia respond poorly to chemotherapy, face a

然而，有几个因素可能会阻碍癌症恶病质市场的增长。研究表明，患有恶病质的癌症患者对化疗反应不佳，面临

higher risk of infection, and have reduced survival

感染风险更高，存活率降低

, with mortality rates ranging from 0–80%, and at least

，死亡率从0-80%不等，至少

30% of cancer patients

30%的癌症患者

die from cachexia rather than the cancer itself.

死于恶病质而不是癌症本身。

Moreover, cancer cachexia treatment poses a

此外，癌症恶病质的治疗 poses a

significant economic burden

显著的经济负担

and disrupts patients' overall well-being and QOL. Furthermore, the cancer cachexia market growth may be offset by

并且破坏患者的整体健康和生活质量。此外，癌症恶病质市场的增长可能会被

failures and discontinuation of emerging therapies

新兴疗法的失败与中断

，

unaffordable pricing

无法承受的定价

，

market access and reimbursement issues

市场准入和报销问题

, and a

，以及一个

shortage of healthcare specialists

医疗专家短缺

. In addition, the

此外，

undiagnosed, unreported cases and the unawareness

未确诊、未报告的病例以及缺乏认识

about the disease may also impact the cancer cachexia market growth.

关于该疾病的信息也可能影响癌症恶病质市场的增长。

Cancer Cachexia Market Report Metrics

癌症恶病质市场报告指标

Details

详情

Study Period

学习期

2020–2034

Coverage

覆盖范围

7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].

7MM［美国、欧盟4国（德国、法国、意大利和西班牙）和英国以及日本］。

Cancer Cachexia Market CAGR

癌症恶病质市场复合年增长率

8.9 %

Cancer Cachexia Market Size in 2024

2024年癌症恶病质市场规模

USD 475 Million

4.75亿美元

Key Cancer Cachexia Companies

关键癌症恶病质公司

Pfizer, Actimed Therapeutics, Endevica Bio, AVEO Oncology (an LG Chem company), Helsinn Healthcare, Ono Pharmaceutical, and others

辉瑞、Actimed Therapeutics、Endevica Bio、AVEO Oncology（LG化学公司旗下）、Helsinn Healthcare、小野制药等其他公司

Key Pipeline Cancer Cachexia Therapies

关键的癌症恶病质治疗管道

Ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1; MT-102), TCMCB07, Rilogrotug (AV-380), ADLUMIZ, and others

波内塞罗单抗（PF-06946860）、S-吲哚洛尔苯甲酸酯（ACM-001.1；MT-102）、TCMCB07、里洛格鲁图（AV-380）、ADLUMIZ 等其他药物

Scope of the

范围

Cancer Cachexia

癌症恶病质

Market Report

市场报告

Therapeutic Assessment:

治疗评估：

Cancer Cachexia current marketed and emerging therapies

癌症恶病质当前市场上的和新兴的疗法

Cancer Cachexia

癌症恶病质

Market Dynamics:

市场动态：

Key Market Forecast Assumptions of Emerging Cancer Cachexia Drugs and Market Outlook

新兴癌症恶病质药物的关键市场预测假设与市场展望

Competitive Intelligence Analysis:

竞争情报分析：

SWOT analysis and Market entry strategies

SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Cancer Cachexia Market Access and Reimbursement

未满足的需求、关键意见领袖的观点、分析师的观点、癌症恶病质市场准入与报销

Download the report to understand which factors are driving cancer cachexia market trends @

下载报告以了解哪些因素正在推动癌症恶病质市场趋势 @

Cancer Cachexia Drug Treatment

癌症恶病质药物治疗

Table of Contents

Key Insights

关键见解

Report Introduction

报告介绍

Cancer Cachexia Market Overview at a Glance

癌症恶病质市场概况一览

3.1

Market Share (%) Distribution by Therapies in the 7MM in 2024

2024年七大市场（7MM）中各疗法市场份额（%）分布

3.2

Market Share (%) Distribution by Therapies in the 7MM in 2034

2034年七大市场中各疗法的市场份额（%）分布

Executive Summary

执行摘要

Key Events

关键事件

Disease Background and Overview

疾病背景与概述

6.1

Introduction

简介

6.2

Causes and Risk Factors

原因和风险因素

6.3

Pathophysiology

病理生理学

6.3.1

Role of Pain in the Pathophysiology of Cancer Cachexia

疼痛在癌症恶病质病理生理学中的作用

6.4

Clinical Manifestations

临床表现

6.5

Laboratory Manifestations

实验室表现

6.6

Staging

分期

6.7

Diagnosis

诊断

6.7.1

Differential Diagnosis

鉴别诊断

6.7.2

Diagnostic Algorithm

诊断算法

6.7.3

Diagnostic Guidelines and Recommendations

诊断指南与建议

6.8

Treatment and Management

治疗与管理

6.8.1

Treatment Algorithm

治疗算法

6.8.2

Treatment Guidelines and Recommendations

治疗指南与建议

Methodology

方法论

Epidemiology and Patient Population

流行病学与患者群体

8.1

Key Findings

主要发现

8.2

Assumptions and Rationale: The 7MM

假设与理由：7MM

8.2.1

Diagnosed Prevalent Cases of Cancer Cachexia

癌症恶病质的诊断流行病例

8.2.2

Gender-specific Cases of Cancer Cachexia

性别特异性癌症恶病质病例

8.2.3

Tumor Type-specific Cases of Cancer Cachexia

肿瘤类型特异性的癌症恶病质病例

8.2.4

Age-specific Cases of Cancer Cachexia

癌症恶病质的年龄特异性病例

8.3

Total Diagnosed Prevalent Cases of Cancer Cachexia in the 7MM

7MM中癌症恶病质的总诊断患病数

8.4

The US

美国

8.4.1

Total Diagnosed Prevalent Cases of Cancer Cachexia in the US

美国癌症恶病质的总诊断患病数

8.4.2

Gender-specific Cases of Cancer Cachexia in the US

美国性别特异性的癌症恶病质病例

8.4.3

Tumor Type-specific Cases of Cancer Cachexia in the US

美国肿瘤类型特异性的癌症恶病质病例

8.4.4

Age-specific Cases of Cancer Cachexia in the US

美国癌症恶病质的年龄特异性病例

8.5

EU4 and the UK

EU4 与英国

8.5.1

Total Diagnosed Prevalent Cases of Cancer Cachexia in EU4 and the UK

欧盟四国及英国癌症恶病质的总诊断患病人数

8.5.2

Gender-specific Cases of Cancer Cachexia in EU4 and the UK

欧盟四大国和英国癌症恶病质的性别特异性病例

8.5.3

Tumor Type-specific Cases of Cancer Cachexia in EU4 and the UK

欧盟四大国和英国癌症恶病质的肿瘤类型特异性病例

8.5.4

Age-specific Cases of Cancer Cachexia in EU4 and the UK

欧盟四大国和英国癌症恶病质的年龄特异性病例

8.6

Japan

日本

8.6.1

Total Diagnosed Prevalent Cases of Cancer Cachexia in Japan

日本癌症恶病质的总诊断患病病例数

8.6.2

Gender-specific Cases of Cancer Cachexia in Japan

日本癌症恶病质的性别特异性病例

8.6.3

Tumor Type-specific Cases of Cancer Cachexia in Japan

日本肿瘤类型特异性的癌症恶病质病例

8.6.4

Age-specific Cases of Cancer Cachexia in Japan

日本癌症恶病质的年龄特异性病例

Patient Journey

患者旅程

Marketed Drugs

已上市药物

10.1

ADLUMIZ (anamorelin hydrochloride): Helsinn Healthcare/Ono Pharmaceutical

ADLUMIZ（盐酸阿那莫林）：Helsinn Healthcare/Ono Pharmaceutical

10.1.1

Product Description

产品描述

10.1.2

Regulatory Milestones

监管里程碑

10.1.3

Other Developmental Activities

其他发展活动

10.1.4

Clinical Trials Information

临床试验信息

10.1.5

Safety and Efficacy

安全性与有效性

List to be continued in the final report….

将在最终报告中继续列出……

Emerging Drugs

新兴药物

11.1

Key Cross Competition

关键交叉竞赛

11.2

Ponsegromab (PF-06946860): Pfizer

波恩塞格罗单抗 (PF-06946860): 辉瑞

11.2.1

Drug Description

药品说明书

11.2.2

Other Developmental Activities

其他开发活动

11.2.3

Clinical Trials Information

临床试验信息

11.2.4

Safety and Efficacy

安全性与有效性

11.2.5

Analysts' View

分析师的观点

11.3

S-pindolol benzoate (ACM-001.1; MT-102): Actimed Therapeutics

S-吲哚洛尔苯甲酸酯（ACM-001.1；MT-102）：Actimed Therapeutics公司

11.3.1

Drug Description

药品说明书

11.3.2

Other Developmental Activities

其他开发活动

11.3.3

Clinical Trials Information

临床试验信息

11.3.4

Safety and Efficacy

安全性和有效性

11.3.5

Analysts' View

分析师观点

11.4

TCMCB07: Endevica Bio

TCMCB07：Endevica 生物科技

11.4.1

Drug Description

药品说明书

11.4.2

Other Developmental Activities

其他开发活动

11.4.3

Clinical Trials Information

临床试验信息

11.4.4

Safety and Efficacy

安全性与有效性

11.5

Rilogrotug (AV-380): AVEO Oncology (an LG Chem company)

里洛格罗图 (AV-380): AVEO 肿瘤学公司（LG化学旗下公司）

11.5.1

Drug Description

药品说明书

11.5.2

Other Developmental Activities

其他开发活动

11.5.3

Clinical Trials Information

临床试验信息

List to be continued in the final report….

完整报告中待续的列表……

Cancer Cachexia – 7MM Market Analysis

癌症恶病质——7MM市场分析

12.1

Key Findings

主要发现

12.2

Key Market Forecast Assumptions

关键市场预测假设

12.2.1

Cost Assumptions and Rebates

成本假设与回扣

12.2.2

Pricing Trends

定价趋势

12.2.3

Analogue Assessment

模拟评估

12.2.4

Launch Year and Therapy Uptake

上市年份与治疗吸收率

12.3

Market Outlook

市场展望

12.4

Attribute Analysis

属性分析

12.5

Total Market Size of Cancer Cachexia in the 7MM

癌症恶病质在七大市场的总规模

12.6

Market Size of Cancer Cachexia by Therapies in the 7MM

七大市场癌症恶病质按疗法划分的市场规模

12.7

The US

美国

12.7.1

Total Market Size of Cancer Cachexia in the US

美国癌症恶病质的总市场规模

12.7.2

Market Size of Cancer Cachexia by Therapies in the US

美国癌症恶病质按疗法划分的市场规模

12.8

EU4 and the UK

欧盟4国与英国

12.8.1

Total Market Size of Cancer Cachexia in EU4 and the UK

欧盟四大国及英国癌症恶病质的总市场规模

12.8.2

Market Size of Cancer Cachexia by Therapies in EU4 and the UK

欧盟四大国家及英国癌症恶病质治疗市场规模

12.9

Japan

日本

12.9.1

Total Market Size of Cancer Cachexia in Japan

日本癌症恶病质的总市场规模

12.9.2

Market Size of Cancer Cachexia by Therapies in Japan

日本癌症恶病质按疗法划分的市场规模

Key Opinion Leaders' Views

关键意见领袖的观点

Unmet Needs

未满足的需求

SWOT Analysis

SWOT分析

Market Access and Reimbursement

市场准入与报销

16.1

The United States

美国

16.1.1

CMS

内容管理系统

16.2

EU4 and the UK

EU4 和英国

16.2.1

Germany

德国

16.2.2

France

法国

16.2.3

Italy

意大利

16.2.4

Spain

西班牙

16.2.5

The United Kingdom

英国

16.3

Japan

日本

16.3.1

MHLW

厚生劳动省

Appendix

附录

17.1

Acronyms and Abbreviations

缩略语和简称

17.2

Bibliography

参考文献

17.3

Report Methodology

报告方法论

DelveInsight Capabilities

德维尔洞察能力

Disclaimer

免责声明

About DelveInsight

关于DelveInsight

Related Reports